Searchable abstracts of presentations at key conferences in endocrinology

ea0081p508 | Late-Breaking | ECE2022

In Individuals with obesity, resting energy expenditure does not decrease after weight loss with GLP-1 agonist liraglutide

Mohseni Mostafa , Welling Mila , E.H. Meeusen Renate , G.C.L.M. Broeders Wietske , Valk Eline van der , van Rossum Elisabeth

Background: Obesity (BMI< 30 kg/m2) is a chronic and progressive disease, that is associated with many co-morbidities such as cardiovascular and psychiatric diseases, cancer, and arthritis. Lifestyle interventions are the cornerstone of obesity treatment, but when ineffective, anti-obesity pharmacotherapy could be added. In recent years, several anti-obesity agents have been approved, such as the glucagon-like peptide -1 (GLP-1) analogue liraglutide. Liraglutide...

ea0081p585 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Improvements in physiological and psychological status of patients with obesity in response to a combined lifestyle intervention with cognitive behavioral therapy are not necessarily related to successful weight loss

Mohseni Mostafa , Kuckuck Susanne , Meeusen Renate , Lengton Robin , van der Valk Eline , Iyer Anand M. , de Groot Corjan , van den Berg Sjoerd , van Rossum Elisabeth F.C.

Background: Obesity (BMI ≤ 30 kg/m2) is a chronic and relapsing disease, associated with numerous co-morbidities. Lifestyle intervention is the cornerstone of treatment of obesity, and is considered effective when weight loss of ≤ 5% is achieved. Here, we describe changes in physiological, psychological and behavioral health outcomes in response to a multidisciplinary combined lifestyle intervention (CLI).MethodsIn this longitudinal study we evaluated 97...